KalVista Pharmaceuticals (KALV) Competitors

$26.79 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$26.78 0.00 (-0.02%)

As of 05/22/2026 05:36 PM Eastern

KALV vs. IMVT, COGT, XENE, APLS, and GRFS

Should you buy KalVista Pharmaceuticals stock or one of its competitors? MarketBeat compares KalVista Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with KalVista Pharmaceuticals include Immunovant (IMVT), Cogent Biosciences (COGT), Xenon Pharmaceuticals (XENE), Apellis Pharmaceuticals (APLS), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

How does KalVista Pharmaceuticals compare to Immunovant?

KalVista Pharmaceuticals (NASDAQ:KALV) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

KalVista Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$49.08M	29.06	-$109.52M	-$3.46	N/A
Immunovant	N/A	N/A	-$413.84M	-$2.78	N/A

KalVista Pharmaceuticals presently has a consensus price target of $30.60, indicating a potential upside of 14.22%. Immunovant has a consensus price target of $35.33, indicating a potential upside of 3.47%. Given KalVista Pharmaceuticals' higher probable upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Immunovant's return on equity of -65.66% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
Immunovant	N/A	-65.66%	-59.88%

KalVista Pharmaceuticals has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

47.1% of Immunovant shares are held by institutional investors. 4.3% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Immunovant had 20 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 25 mentions for Immunovant and 5 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.89 beat Immunovant's score of 0.36 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	10 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Immunovant beats KalVista Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

In the previous week, KalVista Pharmaceuticals had 5 more articles in the media than Cogent Biosciences. MarketBeat recorded 5 mentions for KalVista Pharmaceuticals and 0 mentions for Cogent Biosciences. KalVista Pharmaceuticals' average media sentiment score of 0.89 beat Cogent Biosciences' score of 0.00 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cogent Biosciences	Neutral
KalVista Pharmaceuticals	Positive

Cogent Biosciences presently has a consensus price target of $43.73, suggesting a potential upside of 33.85%. KalVista Pharmaceuticals has a consensus price target of $30.60, suggesting a potential upside of 14.22%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Cogent Biosciences' return on equity of -104.27% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Cogent Biosciences has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

KalVista Pharmaceuticals has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
KalVista Pharmaceuticals	$49.08M	29.06	-$109.52M	-$3.46	N/A

Summary

Cogent Biosciences beats KalVista Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Xenon Pharmaceuticals?

KalVista Pharmaceuticals (NASDAQ:KALV) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

KalVista Pharmaceuticals currently has a consensus target price of $30.60, indicating a potential upside of 14.22%. Xenon Pharmaceuticals has a consensus target price of $77.07, indicating a potential upside of 42.27%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

KalVista Pharmaceuticals has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$49.08M	29.06	-$109.52M	-$3.46	N/A
Xenon Pharmaceuticals	$7.50M	698.22	-$345.91M	-$4.70	N/A

In the previous week, KalVista Pharmaceuticals had 3 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 5 mentions for KalVista Pharmaceuticals and 2 mentions for Xenon Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.89 beat Xenon Pharmaceuticals' score of 0.62 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

KalVista Pharmaceuticals has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Xenon Pharmaceuticals' return on equity of -49.23% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Summary

Xenon Pharmaceuticals beats KalVista Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Apellis Pharmaceuticals?

Apellis Pharmaceuticals (NASDAQ:APLS) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 6.5% of Apellis Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Apellis Pharmaceuticals and Apellis Pharmaceuticals both had 5 articles in the media. KalVista Pharmaceuticals' average media sentiment score of 0.89 beat Apellis Pharmaceuticals' score of 0.25 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apellis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apellis Pharmaceuticals has a beta of -0.24, meaning that its stock price is 124% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

Apellis Pharmaceuticals has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apellis Pharmaceuticals	$1.11B	4.75	$22.39M	$1.02	40.23
KalVista Pharmaceuticals	$49.08M	29.06	-$109.52M	-$3.46	N/A

Apellis Pharmaceuticals has a net margin of 12.06% compared to KalVista Pharmaceuticals' net margin of 0.00%. Apellis Pharmaceuticals' return on equity of 39.71% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apellis Pharmaceuticals	12.06%	39.71%	13.20%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Apellis Pharmaceuticals currently has a consensus price target of $35.72, indicating a potential downside of 12.94%. KalVista Pharmaceuticals has a consensus price target of $30.60, indicating a potential upside of 14.22%. Given KalVista Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Summary

Apellis Pharmaceuticals beats KalVista Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Grifols?

Grifols (NASDAQ:GRFS) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Grifols has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.64	$454.82M	$0.19	42.00
KalVista Pharmaceuticals	$49.08M	29.06	-$109.52M	-$3.46	N/A

In the previous week, KalVista Pharmaceuticals had 3 more articles in the media than Grifols. MarketBeat recorded 5 mentions for KalVista Pharmaceuticals and 2 mentions for Grifols. KalVista Pharmaceuticals' average media sentiment score of 0.89 beat Grifols' score of 0.14 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has a net margin of 5.54% compared to KalVista Pharmaceuticals' net margin of 0.00%. Grifols' return on equity of 6.21% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Grifols currently has a consensus price target of $10.00, suggesting a potential upside of 25.31%. KalVista Pharmaceuticals has a consensus price target of $30.60, suggesting a potential upside of 14.22%. Given Grifols' higher probable upside, analysts clearly believe Grifols is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Grifols has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

Summary

Grifols beats KalVista Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get KalVista Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KALV vs. The Competition

Export

Metric	KalVista Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.43B	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-7.74	17.79	21.21	25.65
Price / Sales	29.06	336.21	554.38	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	-72.41	5.86	10.37	7.14
Net Income	-$109.52M	$74.99M	$3.57B	$335.98M
7 Day Performance	0.13%	3.11%	6.40%	4.15%
1 Month Performance	36.47%	-3.05%	3.53%	2.54%
1 Year Performance	133.57%	34.38%	34.04%	35.06%

KalVista Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KALV KalVista Pharmaceuticals	2.9355 of 5 stars	$26.79 flat	$30.60 +14.2%	+133.6%	$1.43B	$49.08M	N/A	100
IMVT Immunovant	1.7111 of 5 stars	$26.53 -3.5%	$32.44 +22.3%	+136.2%	$5.60B	N/A	N/A	120	Earnings Report
COGT Cogent Biosciences	2.3054 of 5 stars	$31.36 -4.0%	$43.73 +39.4%	+577.8%	$5.58B	N/A	N/A	80
XENE Xenon Pharmaceuticals	3.6029 of 5 stars	$53.71 -1.3%	$77.07 +43.5%	+82.1%	$5.26B	$7.50M	N/A	210
APLS Apellis Pharmaceuticals	1.8334 of 5 stars	$41.03 flat	$35.72 -12.9%	+135.3%	$5.25B	$1.11B	40.23	770	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KALV) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

KalVista Pharmaceuticals (KALV) Competitors

KALV vs. IMVT, COGT, XENE, APLS, and GRFS

How does KalVista Pharmaceuticals compare to Immunovant?

Summary

How does KalVista Pharmaceuticals compare to Cogent Biosciences?

Summary

How does KalVista Pharmaceuticals compare to Xenon Pharmaceuticals?

Summary

How does KalVista Pharmaceuticals compare to Apellis Pharmaceuticals?

Summary

How does KalVista Pharmaceuticals compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV vs. The Competition

KalVista Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

KalVista Pharmaceuticals (KALV) Competitors

KALV vs. IMVT, COGT, XENE, APLS, and GRFS

How does KalVista Pharmaceuticals compare to Immunovant?

Which has stronger earnings & valuation, KALV or IMVT?

Do analysts prefer KALV or IMVT?

Is KALV or IMVT more profitable?

Which has more volatility & risk, KALV or IMVT?

Do institutionals & insiders believe in KALV or IMVT?

Does the media favor KALV or IMVT?

Summary

How does KalVista Pharmaceuticals compare to Cogent Biosciences?

Does the media favor COGT or KALV?

Do analysts recommend COGT or KALV?

Is COGT or KALV more profitable?

Which has more risk and volatility, COGT or KALV?

Which has better earnings and valuation, COGT or KALV?

Summary

How does KalVista Pharmaceuticals compare to Xenon Pharmaceuticals?

Do analysts rate KALV or XENE?

Which has stronger earnings & valuation, KALV or XENE?

Does the media favor KALV or XENE?

Do insiders & institutionals believe in KALV or XENE?

Which has more risk and volatility, KALV or XENE?

Is KALV or XENE more profitable?

Summary

How does KalVista Pharmaceuticals compare to Apellis Pharmaceuticals?

Do insiders and institutionals believe in APLS or KALV?

Does the media prefer APLS or KALV?

Which has more volatility and risk, APLS or KALV?

Which has preferable earnings & valuation, APLS or KALV?

Is APLS or KALV more profitable?

Do analysts rate APLS or KALV?

Summary

How does KalVista Pharmaceuticals compare to Grifols?

Which has preferable valuation & earnings, GRFS or KALV?

Does the media prefer GRFS or KALV?

Is GRFS or KALV more profitable?

Do analysts rate GRFS or KALV?

Which has more risk & volatility, GRFS or KALV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV vs. The Competition

KalVista Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools